Aeglea BioTherapeutics, Inc. (AGLE) Income Statement Analysis

See more : Hikari Tsushin, Inc. (HKTGF) Income Statement Analysis – Financial Results

Complete financial analysis of Aeglea BioTherapeutics, Inc. (AGLE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aeglea BioTherapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

PT Ancora Indonesia Resources Tbk (OKAS.JK) Income Statement Analysis – Financial Results
Pepper Food Service Co., Ltd. (3053.T) Income Statement Analysis – Financial Results
Neuren Pharmaceuticals Limited (NURPF) Income Statement Analysis – Financial Results
Karex Berhad (5247.KL) Income Statement Analysis – Financial Results
Advanced Deposition Technologies, Inc. (ADTC) Income Statement Analysis – Financial Results

Aeglea BioTherapeutics, Inc. (AGLE)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.aeglea.com

About Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Metric	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	2.33M	18.74M	0.00	0.00	3.89M	5.21M	4.63M	6.09M	0.00
Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	2.33M	18.74M	0.00	0.00	3.89M	5.21M	4.63M	6.09M	0.00
Gross Profit Ratio	100.00%	100.00%	0.00%	0.00%	100.00%	100.00%	100.00%	100.00%	0.00%
Research & Development	58.58M	57.07M	59.64M	64.60M	36.72M	22.82M	18.14M	11.45M	6.83M
General & Administrative	28.53M	27.32M	21.84M	15.73M	12.63M	10.07M	8.39M	5.95M	2.07M
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	28.53M	27.32M	21.84M	15.73M	12.63M	10.07M	8.39M	5.95M	2.07M
Other Expenses	-7.00K	-122.00K	-5.00K	-63.00K	-57.00K	-42.00K	-36.00K	-2.00K	0.00
Operating Expenses	87.11M	84.39M	81.48M	80.33M	49.35M	32.88M	26.53M	17.40M	8.90M
Cost & Expenses	87.11M	84.39M	81.48M	80.33M	49.35M	32.88M	26.53M	17.40M	8.90M
Interest Income	837.00K	111.00K	593.00K	2.14M	1.17M	482.00K	244.00K	22.00K	1.00K
Interest Expense	837.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	1.57M	1.58M	996.00K	418.00K	293.00K	249.00K	132.00K	89.00K	19.00K
EBITDA	-84.78M	-65.65M	-80.49M	-80.33M	-44.06M	-27.68M	-21.77M	-11.23M	-7.44M
EBITDA Ratio	-3,640.23%	-350.33%	0.00%	0.00%	-1,133.10%	-531.72%	-470.48%	-184.49%	0.00%
Operating Income	-84.78M	-65.65M	-81.48M	-80.33M	-45.46M	-27.68M	-21.91M	-11.32M	-8.90M
Operating Income Ratio	-3,640.23%	-350.33%	0.00%	0.00%	-1,169.32%	-531.72%	-473.34%	-185.95%	0.00%
Total Other Income/Expenses	830.00K	-11.00K	588.00K	2.08M	-57.00K	-42.00K	-36.00K	20.00K	-1.44M
Income Before Tax	-83.95M	-65.66M	-80.89M	-78.25M	-44.35M	-27.24M	-21.70M	-11.30M	-10.35M
Income Before Tax Ratio	-3,604.59%	-350.39%	0.00%	0.00%	-1,140.64%	-523.27%	-468.84%	-185.62%	0.00%
Income Tax Expense	-136.00K	141.00K	-593.00K	-2.56M	-57.00K	-731.00K	-244.00K	-22.00K	1.44M
Net Income	-83.82M	-65.80M	-80.30M	-75.69M	-44.35M	-27.24M	-21.70M	-11.30M	-10.35M
Net Income Ratio	-3,598.75%	-351.14%	0.00%	0.00%	-1,140.64%	-523.27%	-468.84%	-185.62%	0.00%
EPS	-24.86	-25.02	-37.61	-59.23	-53.25	-45.01	-55.40	-24.71	-37.93
EPS Diluted	-24.86	-25.02	-37.61	-59.23	-53.25	-45.01	-55.40	-24.71	-37.93
Weighted Avg Shares Out	3.37M	2.63M	2.13M	1.28M	832.90K	605.13K	391.67K	457.19K	272.80K
Weighted Avg Shares Out (Dil)	3.37M	2.63M	2.13M	1.28M	832.90K	605.13K	391.67K	457.19K	272.80K

Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma

July 27, 2023prnewswire.com

Global rights to pegzilarginase in development for Arginase 1 Deficiency sold to Immedica Pharma for $15 million upfront cash proceeds and up to $100 million of contingent milestone payments Marketing Authorisation Application for pegzilarginase is under review by the European...